Abbott Expands MiniMed Partnership for Dual Glucose-Ketone Sensors

Abbott Laboratories (NYSE:ABT) announced an expanded agreement with MiniMed to commercialize dual glucose-ketone sensors integrated with MiniMed's smart dosing systems. The partnership aims to enable real-time detection of rising ketones in diabetes patients, helping to prevent diabetic ketoacidosis. Financial terms of the agreement were not disclosed.

The Product

The dual sensors measure glucose and ketone levels in real time, providing continuous readings for type 1 and type 2 diabetes patients. The data is integrated with MiniMed's smart dosing systems to automatically adjust insulin delivery.

Pricing and Availability

Abbott and MiniMed have not announced a commercial launch date or pricing. The sensors are expected to undergo regulatory approvals in key markets.

Competition

Abbott faces competition from Dexcom (DXCM) and Medtronic (MDT) in the continuous glucose monitoring market. However, the dual ketone technology could provide a competitive edge.

Potential Impact on Abbott

The new product could boost Abbott's diabetes care revenue, one of its fastest-growing segments. It also deepens the partnership with MiniMed, opening the door for broader future collaboration.